Tissue Regenix Ltd To Present At Jefferies Healthcare Conference In New York

LEEDS, England--(BUSINESS WIRE)--Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) the regenerative medical devices company announces that CEO, Antony Odell will present a corporate overview at the Jefferies Healthcare Conference in New York on Tuesday 7^th June at 13:30 EDT.

The UK-based company utilises patented dCELL® Technology which addresses clinical needs in wound care, orthopaedic and cardiac applications. The Group commercialised DermaPure®, addressing chronic and acute wounds under Tissue Regenix Wound Care Inc. in 2014, and recently established a further US subsidiary, Tissue Regenix Orthopedics, Inc. earlier in 2016 to bring its OrthoPure™ products to the US market.

The presentation will be available on the companies website following the presentation www.tissueregenix.com.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - ‘Tissue Regenix Wound Care Inc.’, as part of its commercialisation strategy for its dCELL® technology platform.